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SUMMARY
Objective: To examine the effectiveness of intramuscular (IM) midazolam versus
intravenous (IV) lorazepam for the treatment of pediatric patients with status epilepti-
cus (SE) in the prehospital care setting.
Methods: This multicenter clinical trial randomized patients diagnosed with SE to
receive either IM midazolam or IV lorazepam administered by paramedics in the pre-
hospital care setting. Included in this secondary analysis were only patients younger
than 18 years of age. Evaluated were the associations of the treatment group (IM vs.
IV) with the primary outcome, defined as seizure cessation prior to emergency depart-
ment (ED) arrival, and with patient characteristics, time to important events, and
adverse events. Descriptive statistics and 99% confidence intervals (CIs) were used for
the analysis.
Results: Of 893 primary study subjects, 120met criteria for this study (60 in each treat-
ment group). There were no differences in important baseline characteristics or sei-
zure etiologies between groups. The primary outcome was met in 41 (68.3%) and 43
(71.7%) of subjects in the IM and IV groups, respectively (risk difference [RD] 3.3%,
99% CI 24.9% to 18.2%). Similar results were noted for those younger than 11 years
(RD1.3%, 99% CI25.7% to 23.1%). Time from initiating the treatment protocol was
shorter for children who received IM midazolam, mainly due to the shorter time to
administer the active treatment. Safety profiles were similar.
Significance: IM midazolam can be rapidly administered and appears to be safe and
effective for the management of children with SE treated in the prehospital setting.
The results must be interpreted in the context of the secondary analysis design and
sample size of the study.
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Although seizures arise from many etiologies, prolonged
seizure activity from any cause is a dangerous neurologic
emergency in both adults and children. Regardless of the
initially precipitating cause, seizures that do not terminate
spontaneously or with early treatment often create positive
feedback loops in which the seizure becomes self-perpetuat-
ing, resulting in status epilepticus (SE). Despite its many
disparate triggers, SE is a relatively homogenous patho-
physiologic process for which the initial acute treatment,
benzodiazepines, is the same regardless of the etiology or
age of the patient.1,2 In the prehospital setting and in the
emergency department (ED), conventional first-line therapy
for patients with SE is intravenous (IV) diazepam or loraze-
pam.2,3 However, establishing an IV line in convulsing
patients, especially in the prehospital setting, can be chal-
lenging and can delay treatment. Intramuscular (IM) deliv-
ery of midazolam has been advocated as an alternative
treatment, but prior to 2012, it had not been demonstrated to
be as safe or effective as IV treatment.4,5
The Rapid Anticonvulsant Medication Prior to Arrival
Trial (RAMPART) was a randomized controlled clinical
trial designed to determine whether IMmidazolam was non-
inferior to IV lorazepam in adults and children with prehos-
pital SE.6 Published in 2012, RAMPART showed that those
randomized to IM midazolam were more likely to have ter-
minated seizures prior to ED arrival and were less likely to
require hospital ward or intensive care unit (ICU) admis-
sion. RAMPART included pediatric patients because chil-
dren and adolescents constitute a substantial proportion of
those with prehospital SE. Preliminary surveys were
performed to ensure that the study population would have a
sufficient representation of children. Given the consistency
of the underlying biology of SE in adults and children,
RAMPART was powered to test the primary noninferiority
hypothesis in the overall cohort with results applicable to
the general population of patients. Although it was not
designed to evaluate efficacy separately in either the adult
or pediatric subpopulation, the data obtained included a
large number of nonadult patients.
The RAMPART study represents the largest prospective
clinical trial experience with prehospital SE in children and
adolescents. The goal of this study is to describe and clini-
cally characterize this unique cohort. Post hoc subgroup
analyses by age and safety outcomes by age are also
explored.
Methods
Study design and setting
This study is a secondary analysis of the RAMPART clin-
ical trial database focusing on patients younger than
18 years of age. The setting was prehospital and included
33 emergency medical services (EMS) agencies in the
United States and involved 4,314 paramedics trained to
enroll patients. A total of 79 hospitals were able to receive
enrolled patients. RAMPART was a prospective intention-
to-treat noninferiority trial conducted under exception from
informed consent (EFIC) for emergency research (21 Code
of Federal Regulations 50.24). Institutional review board
approval was obtained locally by all participating sites.
Details of the study have been reported previously and are
available elsewhere.6,7
Selection of participants
Participants were enrolled in RAMPART in the prehospi-
tal setting after being evaluated by paramedics and found to
be in SE. Participants were adults of any size or children
with an estimated body weight of ≥13 kg. Estimated weight
was determined by an adaption of a length-based weight
estimation tool.8 More details of the tool’s development for
this study are available through the online protocol (see
Table 5).9 The trial used the contemporary operational defi-
nition of SE; seizure activity persisting for >5 min or lack
of return to baseline function between seizures within a
5 min interval.10 Excluded were those in which the seizures
required alternate treatments (major trauma, hypoglycemia,
cardiac arrest, heart rate of <40 beats per minute) or patients
with a known allergy to study medication. Additional
exclusions were patients who opted out (defined as wearing
a bracelet marked “RAMPART declined”), prisoners,
known pregnancy, or known enrollment in another clinical
study.
For the current analysis, the group of interest was the
RAMPART pediatric population, defined as all participants
younger than 18 years of age. To further examine for poten-
tial age-group–based differences, the pediatric patient study
population was also subdivided into the following age
groups; 0–5, 6–10, and 11–17 years of age. These age
groupings were utilized for the following reasons: (1) the
febrile seizure range is usually up to 5 years of age and this
is the “preschool” age, and (2) using narrower age ranges
for groups would result in very small numbers in each age
group. We also examined the primary outcome result for the
group of “children” defined as younger than 11 years of
age. Because febrile seizures are unique to pediatric
patients, we examined certain features of patients with that
etiology. Sensitivity analyses were performed to determine
whether any part of the analysis was markedly altered by
small changes to these thresholds.
Interventions
All participants in RAMPART received active treatment
with either IM midazolam or IV lorazepam at one of two
doses. Study intervention was initiated by opening an instru-
mented study box containing a study drug kit. Each kit con-
tained two color-coded shrink-wrapped study drug bundles,
one for each dose tier, consisting of one IM autoinjector
(Investigational Midazolam Autoinjector, Meridian Medi-
cal Technologies, Columbia, MD, U.S.A.) and one pre-
filled IV syringe (Carpuject System, Hospira, Lake Forest,
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IL, U.S.A.). All adults and those children with an estimated
weight of more than 40 kg received 10 mg midazolam IM
followed by IV placebo or IM placebo followed by 4 mg lo-
razepam IV. In children with estimated weights of 13–
40 kg, the active treatment was 5 mg midazolam IM or
2 mg lorazepam IV. Blinding and simple randomization
with equal allocation were achieved using a double dummy
strategy in which each kit was randomly assigned either pla-
cebo-IM-medication/active-IV-medication or active-IM-
medication/placebo-IV-medication at the central pharmacy.
All subjects were treated with the IM autoinjector, followed
immediately by obtaining venous access and treatment with
the IV syringe. If IV access could not be obtained, intraos-
seous (IO) access was permitted and considered to be a vas-
cular access route equivalent to IV access. In the event that
the seizure activity continued for >10 min, rescue medica-
tion therapy, based on local EMS protocol, was adminis-
tered.
Methods and measurements
Study measurements in the prehospital phase were under-
taken utilizing a voice-recorded and time-stamped data log-
ger that was integrated into the study box. The voice and
time recorder was automatically activated when the study
box was opened. Data points collected by EMS personnel
included time IM medication given, time IV access
obtained, time IV medication given, time convulsions
stopped if applicable, and whether the patient was still con-
vulsing at the time of hospital arrival. Paramedics were
trained to explicitly verbalize these events when they
occurred, which were captured by the voice recorder. Time
stamps were abstracted from the recordings at the study
clinical coordinating center.
Once the patient arrived in the ED, trained study coor-
dinators or study physicians queried the treating ED phy-
sician to determine if the patient was still thought to be
seizing upon arrival at the receiving ED (the primary
outcome). Other measurements, including patient demo-
graphics, medical history, need for endotracheal intuba-
tion, hospitalization, ICU care, and length of stay were
collected prospectively in the ED, and if hospitalized,
during the inpatient stay and at the time of hospital dis-
charge.
Outcomes
The primary outcome was termination of the seizure prior
to ED arrival as determined by the attending ED physician.
Secondary outcomes included the time intervals from box
open to termination of convulsions, from box open to active
drug administration, and from active drug administration to
termination of convulsions. We also examined a number of
other clinical parameters and events such as seizure
etiology, need for rescue medication, need for hospitaliza-
tion or ICU care, endotracheal intubation, recurrent seizure
within 12 h of ED arrival, and mortality.
Analysis
Baseline patient characterizes and hospital events were
reported using number of events and proportions for cate-
gorical outcomes with associated 99% confidence intervals
(CIs) for binomial proportions or means and standard devia-
tions when describing the entire pediatric study population
characteristics. Between-group data were analyzed using
descriptive statistics to characterize baseline demographics
and clinical outcome variables. For differences between
treatment groups, categorical variables were compared by
differences in proportions with associated 99% CIs, and for
continuous data we reported differences in means and the
associated 99% CIs. Because this was a secondary analysis,
no a priori sample size calculation was performed and a
noninferiority analysis was not utilized for the primary out-
come. It must be emphasized that 99% CIs were used
because of the number of comparisons and features evalu-
ated; this choice resulted in wider (and more conservative)
confidence intervals than the more traditional 95% CI.
Finally, formal statistical testing to generate p-values was
not done for a variety of reasons: subjects were not random-
ized by age strata, it was a secondary analysis, and study
sample size was not sufficient to control for potential type 2
errors. Data analyses were performed using SAS version 9.2
or higher (SAS, Cary, NC, U.S.A.).
Results
Clinical characteristics
The RAMPART pediatric study population consisted of
120 patients between the ages of 0 and 17 years of age
(Fig. 1), with the highest prevalence of enrollments in pre-
school-age children. Pediatric patients accounted for 13.4%
of 893 patients in the entire RAMPART study. The mean
age was 6.7 years (99% CI 5.6–7.8). Figure 2 shows the
overall age distribution. For the age subgroups defined in
the methods, 61 were 0–5 years, 35 were 6–10 years and,
24 were 11–17 years of age. Two patients enrolled (ages
9 months and 1 year old) that violated protocol as a result
of misapplication of the length-based weight estimation tool
were not included in the analysis.
Race and ethnicity are shown in the Table 1. These
generally reflected the demographics of the communities
in which the study was conducted. Race and ethnicity in
the pediatric cohort differed slightly from that of the over-
all study cohort (data not shown). This is likely the effect
of a limited number of communities in which children
were not enrolled for some part or the entirety of the
study’s duration.
About one third of the subjects had a new-onset seizure,
whereas the remainder had a prior history of seizure. Fever
was considered to be the seizure etiology in 23 of 105 sub-
jects (21.9%; 99% CI 11.5–32.3%) with a known etiology
(10 in the IV group and 13 in the IM group). Medication
noncompliance was a relatively infrequent cause of seizures
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(n = 12 of 105 patients; 11.4%, 99% CI 3.4–19.4%). Ten
percent of pediatric patients were ultimately determined to
have nonepileptic spells, and the majority of these were psy-
chogenic seizures.
Rescue medication was required in the prehospital setting
in only 11.7% (99% CI 4.1–19.2%) of all study patients.
There were no deaths among the 120 pediatric patients.
Among the 120 pediatric subjects, 57 were hospitalized,
with 21 of these admitted to the ICU. Thirteen subjects over-
all were intubated.
There were 23 patients with a final diagnosis in the
medical record of febrile seizures. Two of these patients
were 6 years of age and one was 8 years of age (it was
unclear why these patients who were older than 5 years
of age were diagnosed with febrile seizures). For the
patients with febrile seizures, 10 were hospitalized, of
1023 Paents Enrolled in RAMPART
893 Subjects Comprised the Enre
RAMPART Study Populaon
120 Paents Age < 18 Years Included in the
Pediatric Age Group Study
60 Paents Randomized to
IM Midazolam
60 Paents Randomized to
IV Lorazepam
130 Excluded Due to
Repeat Enrollment
773 Excluded Due to Age >
18 Years of Age
Figure 1.
Flow chart describing the selection of
the pediatric study population (for
more details see the RAMPART
study report).6
Epilepsia ILAE
Figure 2.
Distribution and treatment outcomes
of the study popluation by year of age;
IV, intravenous lorazepam; IM,
intramuscular midazolam.
Epilepsia ILAE
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whom 4 went to the ICU, 2 required endotracheal intuba-
tion, and 14 met the primary outcome of seizure cessa-
tion prior to hospital arrival. The table details the overall
study patient population characteristics and those same
characteristics by age group (Table 1).
Primary outcome
In the overall pediatric group, 60 patients were random-
ized to the IM midazolam group and 60 to the IV lorazepam
group. There were no major differences in patient demo-
graphics, the cause of status epilepticus, or the proportion of
patients receiving each dose tier.
For the primary outcome of seizure cessation prior to ED
arrival, 41 (68.3%) of 60 patients who received treatment
with IM midazolam met the primary outcome, as compared
to 43 (71.6%) of 60 treated with IV lorazepam (risk differ-
ence = 3.3%; 99% CI 24.9% to 18.2%). In addition, for
children younger than 11 years of age, 32 (68.1%) of 47 and
34 (69.4%) of 49 patients in the IM and IV groups, respec-
tively, met the primary outcome (risk difference = 1.3%,
99% CI25.7% to 23.1%).
Secondary outcomes
Point estimates of the secondary outcome measures all
favored IMmidazolam. Fewer patients in the IMmidazolam
group who were hospitalized had recurrent seizures, were
intubated, or required ICU care. The mean length-of-stay
(excluding those who were not admitted rather than consid-
ering them as zero day lengths of stay) was 2.6 days in the
IM group compared to 2.0 days in the IV group, but median
lengths of stay were similar.
When stratified by the defined age subgroups, similar
results were noted for patient characteristics, seizure etiol-
ogy and characteristics, in-hospital events, and the primary
outcome. The point estimates for treatment differences
favored the IV group for the two older age strata (IM ther-
apy was favored for those younger than 6 years of age), but
again the number of patients per group is very small and
caution must be used when evaluating these subgroup
results (see the Table 1).
Time interval outcomes
Figure 3A shows the distribution of times from study box
opening to treatment, study box opening to seizure termina-
tion, and from treatment to seizure termination. As a
comparison, Figure 3B shows the same data for the adult
(≥18 years old) RAMPART study patients. In both groups,
the same trends can be seen—particularly time from study
box opening to seizure termination appears to be faster for
patients treated with IM midazolam (no formal statistical
testing was done). Not surprisingly, it was noted that time to
initiation of active treatment may be shorter for those
receiving IM midazolam as compared to IV lorazepam, but
the time from active treatment to seizure termination was
shorter in the IV lorazepam group. The same times to events
as recorded by the data logger also showed similar trends
among the three age strata (Fig. 4A, B, and C).
Median time intervals from first treatment encounter
(defined as the IM dose; either active drug or placebo) to
hospital ED arrival were 16.5 min (13.8 to 25.1 min; 25th to
75th percentiles) for the IM group and 19.6 min (15.0 to
27.1 min) for the IV group.
Discussion
The RAMPART study clearly demonstrated that IM mi-
dazolam is a safe and effective alternative therapy for the
treatment of SE when used by paramedics in the prehospi-
tal setting in a population inclusive of both adult and
pediatric patients. It also highlighted findings consistent
with underlying assumptions that permitted including
A
B
Figure 3.
(A, B) Time intervals to predefined clinical treatment and out-
come events (as described on the figures; note the time intervals
on the x-axis are not the same for each figure due to scale and out-
liers). Boxes are the interquartile ranges, bold vertical lines within
boxes are median times, whisker bars are 1.5 times the interquar-
tile range, and circles represent outliers.
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adults and children in the parent trial. Furthermore, this
secondary analysis of the RAMPART pediatric cohort
implies there is likely an acceptable safety profile within
reasonable margins of confidence. A survey of experts
found they clearly favor lorazepam as the first-line treat-
ment of choice for SE in general, and guidelines suggest
that lorazepam is the preferred agent when IV therapy is
utilized.2,11 The recent Pediatric Seizure Study, however,
found that IV lorazepam offered no benefit over IV diaze-
pam for treating children with SE in the ED, and therefore
questions the concept of lorazepam superiority, at least in
children.12 Because many EMS systems have adopted IM
midazolam as a treatment for SE, the findings add impor-
tant observations needed to continue treatment protocols
and policies for pediatric patients.
Prior studies have demonstrated that midazolam and non-
IV routes of rapid-acting benzodiazepine anticonvulsant
medications are effective and desirable. A meta-analysis of
midazolam versus diazepam showed that non-IV midazo-
lam was safe and effective in children and adults.13 One
study found nasal midazolam to be effective for children
with prolonged febrile seizures treated in the ED, and
another found overwhelming preference by caregivers in
Europe for using nasal or buccal midazolam for sei-
zures.14,15 Our study adds to prior work in finding the IM
route to be a reasonable alternative to IV medication when
treating SE in the prehospital setting. Anecdotally, we noted
preference for this route of administration among parents,
school nurses, and other caretakers when performing the
community consultation required for EFIC.
It is also interesting that a relatively low proportion of
cases of SE was attributed to medication noncompliance
among pediatric patients (11.4%; 99% CI 3.4–19.4%) com-
pared to 38.5% (99% CI 33.7–43.3%) for those older than
17 years of age and 34.9% (99% CI 30.6–39.3%) in the
overall RAMPART study population. It remains to be deter-
mined whether this has age-derived treatment implications
once the patient arrives in the ED, such as immediate admin-
istration of a large dose of the patient’s long-acting anticon-
vulsant or waiting for anticonvulsant serum concentration
results. It was also noted that the 23 patients diagnosed with
febrile seizures tended to respond to treatment and few
required rescue medication, intubation, hospitalization, or
ICU care.
There are a number of limitations to consider when inter-
preting these study results. This was a secondary unplanned
analysis and was not powered to demonstrate noninferiority
for the given outcome in the pediatric subgroup of the
RAMPART study population. Only descriptive data and
estimates of differences and precision of the estimates are
provided. Due to the nature of the study and analysis, no for-
mal, experimentally-derived recommendations and conclu-
sions to the safety and efficacy can be made. Many of the
estimates of patient characteristics, times to events, safety
profiles, and outcome measures were, however, similar to
and consistent with the overall RAMPART study popula-
tion. The findings within the pediatric subgroup are reassur-
ing despite the preceding limitations. The emergent nature
of the study and the fact that it was carried out in the prehos-
A
B
C
Figure 4.
(A, B, C) Time intervals to predefined clinical treatment and out-
come events (as described on the figures; note the time intervals
on the x-axis are not the same for each figure due to scale and out-
liers). Boxes are the interquartile ranges, bold vertical lines within
boxes are median times, whisker bars are 1.5 times the interquar-
tile range, and circles represent outliers.
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pital setting dictated that estimated weights were used and
that children were stratified to one of only two dose tiers.
Some may worry that these broad fixed-dose tiers may
result in doses too high for those at the lower end or too low
for those at the higher of each stratum. We chose this fixed-
dose protocol to avoid the known problems with the more
extreme dosing errors resulting from miscalculation and
measurement error commonly encountered in pediatric
resuscitation efforts.16 The range of doses in mg/kg found at
the extremes of each dose tier were consistent with the wide
ranges reported in clinical use. Our study did not find any
safety issues using this dose schedule but the possibility of
narrower dose tiers could be the subject of future study.
Although a limitation, the study design more accurately
reflected the realities of the emergency prehospital treat-
ment of this disorder. In the absence of such data, a fixed-
tier dosing remains more pragmatic, less susceptible to
errors in administration, and consistent with a favorable
safety profile.
In summary, this analysis of the RAMPART pediatric
cohort reports the demographics and clinical characteristics
of children treated by EMS for SE in the prehospital setting.
Those treated tended to be preschool and young school-aged
children, most of whom had a history of prior seizures. Non-
compliance with medications is a less common cause of SE
than in the overall cohort, but psychogenic nonepileptic
spells are similar in frequency. Although there is insuffi-
cient power to independently assess efficacy and safety out-
comes by intervention in the pediatric subgroup, the
findings are consistent with those of the overall cohort and
support the representativeness of the original analysis. Rates
of hospital and ICU admission, endotracheal intubation, and
recurrent seizure are all favorable in children compared to
the overall cohort, and in IM midazolam compared with IV
lorazepam.
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